Related Experiment Video

Updated: Jun 14, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

37.4K

Talazoparib for the treatment of prostate cancer

Arshit Narang1, Chadi Hage Chehade1, Zeynep Irem Ozay1

  • 1Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Expert Opinion on Pharmacotherapy
|August 30, 2024
PubMed
Abstract

Insights

PARP inhibitors offer a promising treatment for advanced prostate cancer with HRR alterations. Combination therapies, including PARP inhibitors, show potential for improving outcomes in metastatic castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Approximately 25% of advanced prostate cancer cases involve homologous recombination/DNA damage repair (HRR) pathway alterations.
  • PARP inhibitors (PARPi) induce synthetic lethality in HRR-altered tumors, showing promise for metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).

Purpose of the Study:

  • To review the mechanism of action, pharmacokinetics, pharmacodynamics, and clinical data of PARPi, specifically talazoparib, in prostate cancer.
  • To examine clinical trial data from TALAPRO-1, TALAPRO-2, and the ongoing TALAPRO-3 trial.

Main Methods:

  • Review of existing literature on PARP inhibitors in prostate cancer.
  • Analysis of clinical trial data (TALAPRO-1, TALAPRO-2, TALAPRO-3).

Main Results:

  • PARPi, such as talazoparib, demonstrate potential as a treatment for mCRPC and mHSPC in patients with HRR mutations.
  • Combination therapies involving androgen receptor pathway inhibitors (ARPIs) and PARPi are indicated for HRR-mutated mCRPC.

Conclusions:

  • Despite advancements, mCRPC remains a significant challenge, highlighting the need for effective therapies.
  • Genomic testing is crucial for identifying patients who can benefit from PARPi, but access remains a challenge.
  • Further research and improved genomic testing access are essential for optimizing treatment strategies in advanced prostate cancer.
Keywords:
Prostate cancermetastatic castration-resistant prostate cancernext-generation sequencingpoly(adp) ribose polymerase inhibitorstalazoparib

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

14.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K